Systemic fungal infections: an overview.
Increasingly more common, these infections pose diagnostic and therapeutic problems. The distinction between primary infection in healthy hosts and opportunistic infection in the immunocompromised remains clinically useful. Three major diseases in each category are discussed. A promising therapeutic advance is the introduction of orally administered azoles.
Medoff
G
G
Department of Internal Medicine, Washington University School of Medicine, St. Louis.
Kobayashi
G S
GS
D000935:Antifungal Agents / Q000627:therapeutic use; D001228:Aspergillosis / Q000175:diagnosis; D001759:Blastomycosis / Q000175:diagnosis; D002177:Candidiasis / Q000175:diagnosis; D003047:Coccidioidomycosis / Q000175:diagnosis; D003453:Cryptococcosis / Q000175:diagnosis; D006660:Histoplasmosis / Q000175:diagnosis; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000150:complications; D009181:Mycoses / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy; D009894:Opportunistic Infections / Q000150:complications
D000935:Antifungal Agents